Skip to main content

Table 3 Multivariate analysis of the predicting association of clinical factors with occurrence of hyponatremia

From: Furosemide and spironolactone doses and hyponatremia in patients with heart failure

  OR (95% CI) p
Age (per 10-year increase) 1.115 (1.023–1.159) 0.03*
Alcohol consumption 1.112 (1.002–1.273) 0.04*
Male sex 0.947 (0.861–1.047) 0.29
Kidney failure 1.043 (0.945–1.154) 0.39
LVEF ≤45% 0.943 (0.994–1.001) 0.25
Arterial hypertension 0.947 (0.854–1.049) 0.29
Diabetes mellitus 1.114 (1.012–1.224) 0.02*
Previous AMI 1.053 (0.946–1.191) 0.31
Current smoking 1.069 (0.953–1.258) 0.19
Hydrochlorothiazide 0.976 (0.863–1.093) 0.63
250 to 500 mg furosemide 1.138 (1.043–1.344) 0.009*
50 to 100 mg spironolactone 1.197 (1.126–1.484) 0.0003*
β-blocker 0.959 (0.878–1.053) 0.39
Calcium antagonist 0.935 (0.827–1.036) 0.18
ARB 1.049 (0.929–1.249) 0.32
ACEI 1.074 (0.973–1.178) 0.16
Aspirin 0.977 (0.886–1.076) 0.63
Digoxin 0.943 (0.837–1.045) 0.24
  1. Odds ratios (OR) and p values were obtained from the logistic regression analysis. CI Confidence Interval, LVEF Left ventricular ejection fraction, AMI Acute myocardial infarction, ARB Angiotensin II receptor I blocker, ACEI Angiotensin converting enzyme-inhibitor
  2. * Statistically significant differences (p < 0.05)
\